Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial

Enoxaparin is an established therapy for the treatment of patients with acute coronary syndrome (ACS), and bivalirudin is commonly used as the antithrombotic agent during percutaneous coronary intervention (PCI). This study was designed to examine the safety of switching from enoxaparin to bivalirud...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of invasive cardiology 2006-08, Vol.18 (8), p.370-375
Hauptverfasser:	Waksman, Ron, Wolfram, Roswitha M, Torguson, Rebecca L, Okubagzi, Petros, Xue, Zheny, Suddath, William O, Satler, Lowell F, Kent, Kenneth M
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Aged Angioplasty, Balloon, Coronary Anticoagulants - adverse effects Anticoagulants - therapeutic use Coronary Disease - complications Coronary Disease - drug therapy Coronary Disease - therapy Enoxaparin - adverse effects Enoxaparin - therapeutic use Female Hemorrhage - chemically induced Hemorrhage - epidemiology Hirudins - adverse effects Humans Incidence Male Middle Aged Myocardial Infarction - epidemiology Myocardial Infarction - etiology Peptide Fragments - adverse effects Peptide Fragments - therapeutic use Recombinant Proteins - adverse effects Recombinant Proteins - therapeutic use Retreatment Risk Assessment Syndrome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!